Cargando…

Integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism

Many drugs have been shown to be metabolized by the human gut microbiome, but probiotic-driven drug-metabolizing capacity is rarely explored. Here, we developed an integrated metabolomics, culturomics, and bionics framework for systematically studying probiotics-driven drug metabolism. We discovered...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bohai, Kwok, Lai-Yu, Wang, Dandan, Li, Lu, Guo, Shuai, Chen, Yongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908756/
https://www.ncbi.nlm.nih.gov/pubmed/36778014
http://dx.doi.org/10.3389/fphar.2023.1047863
_version_ 1784884432433315840
author Li, Bohai
Kwok, Lai-Yu
Wang, Dandan
Li, Lu
Guo, Shuai
Chen, Yongfu
author_facet Li, Bohai
Kwok, Lai-Yu
Wang, Dandan
Li, Lu
Guo, Shuai
Chen, Yongfu
author_sort Li, Bohai
collection PubMed
description Many drugs have been shown to be metabolized by the human gut microbiome, but probiotic-driven drug-metabolizing capacity is rarely explored. Here, we developed an integrated metabolomics, culturomics, and bionics framework for systematically studying probiotics-driven drug metabolism. We discovered that 75% (27/36 of the assayed drugs) were metabolized by five selected probiotics, and drugs containing nitro or azo groups were more readily metabolized. As proof-of-principle experiments, we showed that Lacticaseibacillus casei Zhang (LCZ) could metabolize racecadotril to its active products, S-acetylthiorphan and thiorphan, in monoculture, in a near-real simulated human digestion system, and in an ex vivo fecal co-culture system. However, a personalized effect was observed in the racecadotril-metabolizing activity of L. casei Zhang, depending on the individual’s host gut microbiome composition. Based on data generated by our workflow, we proposed a possible mechanism of interactions among L. casei Zhang, racecadotril, and host gut microbiome, providing practical guidance for probiotic-drug co-treatment and novel insights into precision probiotics.
format Online
Article
Text
id pubmed-9908756
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99087562023-02-10 Integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism Li, Bohai Kwok, Lai-Yu Wang, Dandan Li, Lu Guo, Shuai Chen, Yongfu Front Pharmacol Pharmacology Many drugs have been shown to be metabolized by the human gut microbiome, but probiotic-driven drug-metabolizing capacity is rarely explored. Here, we developed an integrated metabolomics, culturomics, and bionics framework for systematically studying probiotics-driven drug metabolism. We discovered that 75% (27/36 of the assayed drugs) were metabolized by five selected probiotics, and drugs containing nitro or azo groups were more readily metabolized. As proof-of-principle experiments, we showed that Lacticaseibacillus casei Zhang (LCZ) could metabolize racecadotril to its active products, S-acetylthiorphan and thiorphan, in monoculture, in a near-real simulated human digestion system, and in an ex vivo fecal co-culture system. However, a personalized effect was observed in the racecadotril-metabolizing activity of L. casei Zhang, depending on the individual’s host gut microbiome composition. Based on data generated by our workflow, we proposed a possible mechanism of interactions among L. casei Zhang, racecadotril, and host gut microbiome, providing practical guidance for probiotic-drug co-treatment and novel insights into precision probiotics. Frontiers Media S.A. 2023-01-26 /pmc/articles/PMC9908756/ /pubmed/36778014 http://dx.doi.org/10.3389/fphar.2023.1047863 Text en Copyright © 2023 Li, Kwok, Wang, Li, Guo and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Bohai
Kwok, Lai-Yu
Wang, Dandan
Li, Lu
Guo, Shuai
Chen, Yongfu
Integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism
title Integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism
title_full Integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism
title_fullStr Integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism
title_full_unstemmed Integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism
title_short Integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism
title_sort integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908756/
https://www.ncbi.nlm.nih.gov/pubmed/36778014
http://dx.doi.org/10.3389/fphar.2023.1047863
work_keys_str_mv AT libohai integratingmetabolomicsbionicsandculturomicstostudyprobioticsdrivendrugmetabolism
AT kwoklaiyu integratingmetabolomicsbionicsandculturomicstostudyprobioticsdrivendrugmetabolism
AT wangdandan integratingmetabolomicsbionicsandculturomicstostudyprobioticsdrivendrugmetabolism
AT lilu integratingmetabolomicsbionicsandculturomicstostudyprobioticsdrivendrugmetabolism
AT guoshuai integratingmetabolomicsbionicsandculturomicstostudyprobioticsdrivendrugmetabolism
AT chenyongfu integratingmetabolomicsbionicsandculturomicstostudyprobioticsdrivendrugmetabolism